tiprankstipranks
Trending News
More News >

Carisma Therapeutics Announces Merger with OrthoCellix

Story Highlights
  • Carisma Therapeutics announced a merger with OrthoCellix to focus on regenerative cell therapies.
  • OrthoCellix will own 90% of the combined company, planning a Phase 3 trial for NeoCart®.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Carisma Therapeutics Announces Merger with OrthoCellix

Don’t Miss TipRanks’ Half-Year Sale

Carisma Therapeutics ( (CARM) ) has provided an update.

On June 22, 2025, Carisma Therapeutics announced a merger agreement with OrthoCellix, a subsidiary of Ocugen, to create a Nasdaq-listed company focused on regenerative cell therapies for orthopedic diseases. The merger will result in OrthoCellix owning approximately 90% of the combined entity, with plans to initiate a Phase 3 clinical trial for its NeoCart® technology by the end of 2025, potentially impacting the market for cartilage repair solutions.

The most recent analyst rating on (CARM) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Carisma Therapeutics stock, see the CARM Stock Forecast page.

Spark’s Take on CARM Stock

According to Spark, TipRanks’ AI Analyst, CARM is a Neutral.

Carisma Therapeutics’ overall score reflects its financial instability and valuation concerns as primary weaknesses. The technical analysis provides some positive indicators but is overshadowed by the financial and valuation challenges.

To see Spark’s full report on CARM stock, click here.

More about Carisma Therapeutics

Carisma Therapeutics is a biotechnology company focused on macrophage engineering to develop therapies for fibrosis and cancer. OrthoCellix, a subsidiary of Ocugen, specializes in regenerative cell therapies for orthopedic diseases, with its lead program NeoCart® aimed at repairing knee cartilage defects.

Average Trading Volume: 13,925,722

Technical Sentiment Signal: Sell

Current Market Cap: $18.43M

For detailed information about CARM stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1